Influence of the CYP2C9 & CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India

Indian Journal of Medical Research

Volumn 123, Issue 5, 2006, Pages 665-670

  Rosemary, J ^a   Surendiran, A ^a   Rajan, S ^a   Shashindran, C H ^a   Adithan, C ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CYP2C19; CYP2C9; Metabolism; Phenytoin; South Indians

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; PHENYTOIN;

ADULT; ALLELE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CALCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INDIA; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; HYDROXYLATION; INDIA; MALE; MIXED FUNCTION OXYGENASES; PHENYTOIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33746110878     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002; 12:251-63.
2. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62:287-92.
3. Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 2001; 57:31-6.
4. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. [updated 2005 March 5; cited 2005 Nov 6]. Available from: http://www.imm.ki.se/cypalleles/cyp2c9.htm, accessed on April 30, 2006.
5. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7:51-8.
6. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-9.
7. Aynacioglu AS, Brockmoller J, Bauer S, Sachse C, Guzelbey P, Ongen Z, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48:409-15.
8. Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol 2003; 59:707-9.
9. Jose R, Chandrasekaran A, Sam SS, Gerard N, Chanolean S, Abraham BK, et al. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam Clin Pharmacol 2005; 19:101-5.
10. Sambrook J, Fritsct EF, Maniatis T. Molecular cloning: A laboratory manual, 2nd ed. New York: Cold Spring Harbour Laboratory; 1989.
11. Sviri S, Shpizen S, Leitersdorf E, Levy M, Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther 1999; 65:275-82.
12. Gerson B, Bell F, Chan S. Antiepileptic agents -primidone, phenobarbital, phenytoin, and carbamazepine by reversed-phase liquid chromatography. Clin Chem 1984; 30:105-8.
13. Caraco Y, Muszkat M, Wood AJ. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. Pharmacogenetics 2001; 11:587-96.
14. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbard LE, Gilman AG, editors. Goodman and Gilman's: The pharmacological basis of therapeutics. New York: McGraw-Hill; 2001 p. 528-30.
15. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J 2001; 1:204-10.
16. Lee AY, Kim MJ, Chey WT, Choi J, Kim BG. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol 2004; 60:155-9.
17. Soga Y, Nishimura F, Ohtsuka Y, Araki H, Iwamoto Y, Naruishi H, et al. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci 2004; 74: 827-34.